This defines a genetic resistance-gap in patients with acquired resistance to chemotherapy and EGFR-Abs, similar to the 64% of the cancer cells sampled by ctDNA that had no detectable genetic resistance drivers observed in patients treated with single-agent cetuximab [9]. This evidence concerns the gene EGFR and cancer.